153 related articles for article (PubMed ID: 15770399)
1. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
3. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment for refractory primary biliary cirrhosis?
Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
[TBL] [Abstract][Full Text] [Related]
5. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S; Leoz M; Nazal L; Bruguera M; Parés A
Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.
Hidaka M; Iwasaki S; Matsui T; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Kiyokawa T; Takahashi M; Saibara T; Onishi S; Kawano F
Bone Marrow Transplant; 2010 May; 45(5):912-8. PubMed ID: 19802024
[TBL] [Abstract][Full Text] [Related]
10. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.
Nakai S; Masaki T; Kurokohchi K; Deguchi A; Nishioka M
Am J Gastroenterol; 2000 Jan; 95(1):326-7. PubMed ID: 10638623
[No Abstract] [Full Text] [Related]
12. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
13. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
15. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
Angulo P; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
18. [Possibilities in the treatment of primary biliary cirrhosis].
Lengyel G; Tulassay Z
Orv Hetil; 2005 Jun; 146(23):1245-9. PubMed ID: 15988919
[TBL] [Abstract][Full Text] [Related]
19. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
